US · biotech · hepatitis b
One round we have observed, with the investors the report named. Every figure below came from a named source, and where the company reported the raise to the SEC itself, that is shown beside it.
Series B · May 2025 · $50M
Industry VC lead, Qiming Venture Partners, CDH Investments, HanKang Capital, Sherpa Capital, Genesis Capital, YuanBio VC
Reported by TechStartups
Missing a round, or an investor who was in one? Tell us.